BLIS Technologies Limited (NZE:BLT)
New Zealand · Delayed Price · Currency is NZD 0.0190
0.00 (0.00%)
Jul 16, 2025, 2:16 PM NZST
BLIS Technologies Company Description
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity.
The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance.
It also provides its products in the ENT, immune, dental, and skin areas. The company has operations in New Zealand, Asia Pacific, Europe Middle East and Africa, and North America.
The company was incorporated in 2000 and is based in Dunedin, New Zealand.
BLIS Technologies Limited
| Country | New Zealand |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Scott Johnson |
Contact Details
Address: 399 Moray Place Dunedin, 9016 New Zealand | |
| Phone | 64 3 474 0988 |
| Website | blis.co.nz |
Stock Details
| Ticker Symbol | BLT |
| Exchange | New Zealand Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | NZD |
| ISIN Number | NZBLTE0002S8 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott Johnson | Chief Executive Officer |
| Richard Wingham | Chief Financial Officer |